Modeling preventative strategies against human papillomavirus-related disease in developed countries
about
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study.Testing previous model predictions against new data on human papillomavirus vaccination program outcomes.Women have a preference for their male partner to be HPV vaccinated.Comprehensive control of human papillomavirus infections and related diseasesIs expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.Incremental benefits of male HPV vaccination: accounting for inequality in population uptake.A survey of population-based utility scores for cervical cancer preventionToo late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway.Systematic review of model-based cervical screening evaluations.Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screeningQuadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon.Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs.The next steps in cervical screening.Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.HPV vaccination: acceptance and influencing factors among young men in Germany.Oral and oropharyngeal cancer and the role of sexual behaviour: a systematic review.Long-term HPV type-specific risks for ASCUS and LSIL: a 14-year follow-up of a randomized primary HPV screening trial.Cervical cancer incidence in British Columbia: Predicting effects of changes from Pap to human papillomavirus screening and of changes in screening participation.Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial.Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis.Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening.HPV prophylactic vaccines: lessons learned from 10 years experience
P2860
Q30667372-952F4B89-1A5F-4B25-8ABE-BD3A48EC4629Q30764433-014563E2-A90C-4091-85FB-6E9284A5CF41Q33609959-6D7D9F94-A3AC-43ED-91C1-321589F69C7BQ33772648-83EB7979-0025-469E-98AF-4CFF372DACBEQ33848793-C0425885-2A6F-4812-934B-658A5AB57B87Q33999169-7E507A45-940D-4EEB-9675-864EF4EEDBDDQ35018648-002774FA-6524-43D8-8455-DBE6989C6478Q35127307-D8DDAFE9-0F50-41C8-BD47-5BAECE435AE4Q35568922-84A913FE-F60E-4B91-B7D2-0FE76D0319DAQ35991580-0CA0FDCD-93C2-4F94-AA4F-83E67BC879D4Q36325832-B66FAA2A-3EE0-4589-A32E-BC08770175E6Q36871974-B31F47B5-7965-4132-A458-77E5682C8987Q37130168-EA67C176-A41E-4ADD-A941-5F4B8DE4E4B4Q37273434-9D8205EC-44CC-4BE6-AB88-04E76A7D9BF5Q38229304-0CC670A4-8B04-4E64-B4CC-5509527ED415Q38254337-354F52A0-5C12-4909-92FF-FFB07F560F28Q38255277-44458400-50D6-4BC4-B9D5-F9146732C176Q38380092-D7851F77-9318-4449-BDBC-030527C03005Q38549643-DB39AC72-4374-41A9-B5C5-EF8C32437FAFQ38931505-0205B159-697A-47AE-8352-E86C06AA5DD7Q38958210-DA154A4F-896C-42A5-A882-369128620AA2Q39189708-62743555-CAA4-4FC9-9E52-35AD70A040A8Q39218551-7B63F8BE-C9B1-488E-A56D-9D9AB0F96C0DQ40569845-103A3F34-8055-4A84-BE4F-CACFC2845580Q42204957-B7DC4663-6957-4718-B905-3EEC20766AE3Q42241908-70E34E55-5517-4B03-9341-2A404B145AE2Q44841725-9383FFA2-07B7-4F16-AB04-C2B843179736Q45229241-F589B1C8-B5B4-4807-8D86-9527F8CFEF87Q55397815-8A1F203D-80E5-4840-9315-5A30C09998F8Q56067928-935A157B-54FD-4A46-9972-100F0BA3B50C
P2860
Modeling preventative strategies against human papillomavirus-related disease in developed countries
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Modeling preventative strategi ...... disease in developed countries
@en
Modeling preventative strategi ...... isease in developed countries.
@nl
type
label
Modeling preventative strategi ...... disease in developed countries
@en
Modeling preventative strategi ...... isease in developed countries.
@nl
prefLabel
Modeling preventative strategi ...... disease in developed countries
@en
Modeling preventative strategi ...... isease in developed countries.
@nl
P2093
P2860
P1433
P1476
Modeling preventative strategi ...... disease in developed countries
@en
P2093
Harrell Chesson
Jane J Kim
Johannes Berkhof
Karen Canfell
Shalini L Kulasingam
P2860
P304
P356
10.1016/J.VACCINE.2012.06.091
P407
P478
30 Suppl 5
P50
P577
2012-11-01T00:00:00Z